Singular Genomics Systems Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-1.64	-1.34	-0.59
Change in Accounts Receivable	-0	-0	0.03
Change in Inventory	-0.07	-0.07	-0
Change in Accounts Payable	0.09	0.13	0.03
Change in Other Net Operating Assets	0.26	0.26	-0.01
Operating Cash Flow	-0.9	-1.02	-0.53
Capital Expenditures	-0.05	-0.09	-
Investing Cash Flow	-0.05	-0.09	-
Long-Term Debt Issued	-	1.14	0.14
Short-Term Debt Repaid	-	-0.03	-0.04
Total Debt Repaid	-0.03	-0.03	-0.04
Net Debt Issued (Repaid)	1.05	1.11	0.1
Issuance of Common Stock	-	-	0.22
Financing Cash Flow	1.05	1.11	0.32
Net Cash Flow	0.1	-0	-0.22
Free Cash Flow	-0.95	-1.11	-0.53
Free Cash Flow Margin	-1909.39%	-1888.14%	-1276.90%
Free Cash Flow Per Share	-0.03	-0.04	-0.02
Cash Interest Paid	0.04	0.04	0
Levered Free Cash Flow	-	-0.87	-
Unlevered Free Cash Flow	-	-0.84	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.